Otsuka Pharmaceutical To Acquire Transcend Therapeutics

Otsuka Pharmaceutical Co., Ltd., (Otsuka) has entered into an agreement to fully acquire Transcend Therapeutics, Inc., (Transcend) through its wholly owned subsidiary Otsuka America, Inc. The transaction, valued at up to $1.2 billion, is expected to close in the second quarter of 2026, pending customary closing conditions.

Under the terms of the agreement, Otsuka will pay $700 million to Transcend shareholders at closing, with up to an additional $525 million in contingent payments tied to future sales milestones, bringing the total potential to $1.225 billion.

Founded in 2021 and based in New York City, Transcend is a clinical . . .